Prof Andrew Wei
Honorary (Professorial Fellow)
Department of Medical Biology (WEHI)
558 Scholarly works
4 Projects
HIGHLIGHTS
2025
Research grants (other domestic)
COSMOS-AML; Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML
2024
Research grants (other domestic)
Investigating Clonal Haematopoiesis and Risk Factors for Evolution to Myeloid Neoplasia (ICHROME)
2023
Journal article
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
DOI: 10.1182/blood.20220160902022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752021
Journal article
BCL2 and MCL1 inhibitors for hematologic malignancies
DOI: 10.1182/blood.20200067852021
Journal article
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
DOI: 10.1182/blood.20200101672020
Journal article
BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
DOI: 10.1182/blood-2020-137775
RECENT SCHOLARLY WORKS
2026
Journal article
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
DOI: 10.1038/s41408-025-01429-z2026
Journal article
Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation
DOI: 10.1016/j.bneo.2026.1002262026
Journal article
Abstract SY35-01: Enhancing BH3 mimetic drug induced killing of malignant cells for cancer therapy
DOI: 10.1158/1538-7445.am2026-sy35-012026
Journal article
Abstract 3979: Targeting nicotinamide metabolism with NAMPT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemia
DOI: 10.1158/1538-7445.am2026-39792026
Journal article
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
DOI: 10.1182/blood.20250314802026
Journal article
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
DOI: 10.1182/bloodadvances.20250170832026
Journal article
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
DOI: 10.1182/bloodadvances.20250170832026
Journal article
Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
DOI: 10.1016/j.jtct.2025.12.560